Whirlwind hits FDA, NIH: a Perspective

The Trump administration is less than a week old, but the life sciences public policy environment has already been turned upside down. In an effort to cut through the noise, an entirely subjective account of some of the week’s developments that seem important to me follows. I’ll start by previewing one of next week’s events.

Robert F. Kennedy Jr. is set to face Senate committees next week as HHS secretary nominee. While he’s likely to downplay his anti-vaccine stance, Kennedy’s financial disclosures reveal millions earned from and ongoing stakes in lawsuits against vaccine manufacturers. ...